Compare ODFL & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ODFL | INSM |
|---|---|---|
| Founded | 1934 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.7B | 33.5B |
| IPO Year | 1991 | 2000 |
| Metric | ODFL | INSM |
|---|---|---|
| Price | $207.11 | $152.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 20 | 24 |
| Target Price | $166.84 | ★ $192.27 |
| AVG Volume (30 Days) | 2.1M | ★ 2.7M |
| Earning Date | 02-04-2026 | 02-19-2026 |
| Dividend Yield | ★ 0.59% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.97 | N/A |
| Revenue | ★ $5,574,922,000.00 | $447,022,000.00 |
| Revenue This Year | N/A | $53.83 |
| Revenue Next Year | $2.41 | $138.44 |
| P/E Ratio | $38.20 | ★ N/A |
| Revenue Growth | N/A | ★ 30.34 |
| 52 Week Low | $126.01 | $60.40 |
| 52 Week High | $209.61 | $212.75 |
| Indicator | ODFL | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 81.63 | 36.22 |
| Support Level | $169.99 | $150.80 |
| Resistance Level | $175.79 | $158.98 |
| Average True Range (ATR) | 6.24 | 6.52 |
| MACD | 1.98 | 0.15 |
| Stochastic Oscillator | 99.11 | 10.08 |
Old Dominion Freight Line is the second-largest less-than-truckload carrier in the United States (following FedEx Freight), with more than 250 service centers and 11,000-plus tractors. It is one of the most disciplined and efficient providers in the trucking industry, and its profitability and capital returns are head and shoulders above its peers. Strategic initiatives revolve around boosting network density through market share gains and maintaining industry-leading service (including ultralow cargo claims) via steadfast infrastructure investment.
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.